First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study

Published:2015-07-23 Issue:1 Volume:22 Page:87-95
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Kreuz W.¹,Escuriola Ettingshausen C.¹,Vdovin V.²,Zozulya N.³,Plyushch O.³,Svirin P.²,Andreeva T.⁴,Bubanská E.⁵,Campos M.⁶,Benedik‐Dolničar M.⁷,Jiménez‐Yuste V.⁸,Kitanovski L.⁷,Klukowska A.⁹,Momot A.¹⁰,Osmulskaya N.¹¹,Prieto M.¹²,Šalek S. Z.¹³,Velasco F.¹⁴,Pavlova A.¹⁵,Oldenburg J.¹⁵,Knaub S.¹⁶,Jansen M.¹⁷,Belyanskaya L.¹⁶,Walter O.¹⁶,

Affiliation:

1. HZRM Hämophilie‐Zentrum Rhein Main Frankfurt‐Mörfelden Mörfelden‐Walldorf Germany

2. Izmaylovo Children's Hospital Haematological Centre Moscow Russia

3. The State Haematological Scientific Centre RAMS Moscow Russia

4. St. Petersburg State Healthcare Institution St. Petersburg Russia

5. Children Faculty Hospital with Policlinic Banská Bystrica Slovakia

6. Centro Hospitalar Porto Hospital de Santo António Porto Portugal

7. Children's Hospital Oncology‐Hematology Unit University Medical Center Ljubljana Ljubljana Slovenia

8. Hospital La Paz Madrid Spain

9. Medical Academy Warsaw Poland

10. Altai Hematological Center Altai Russia

11. State Healthcare Institution of Omsk Region Omsk Russia

12. Hospital General Yagüe Castilla Leon Spain

13. University Hospital REBRO Zagreb Croatia

14. Hospital Reina Sofía Córdoba Spain

15. Institute of Experimental Haematology and Transfusion Medicine University Clinic Bonn Bonn Germany

16. Octapharma AG Lachen Switzerland

17. Octapharma Pharmazeutika Produktionsges.mbH Vienna Austria

Funder

Baxter International

Bayer

CSL Behring

Novo Nordisk

Biogen Idec

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.12774

Reference30 articles.

1. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs

2. Prevention of bleeds in hemophilia patients with inhibitors: Emerging data and clinical direction

3. Treatment of patients with inhibitors: cost issues

4. Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: A prospective clinical case series

5. Definitions in Hemophilia

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Low‐dose immune tolerance induction for severe hemophilia A inhibitor patients: Immunosuppressants are generally not necessary for inhibitor‐titer below 200 BU/mL;Pediatric Investigation;2024-06

2. International Council for Standardization in Haematology recommendations for laboratory measurement of factor VIII and FIX type I inhibitors;International Journal of Laboratory Hematology;2023-06-07

3. Determinants of successful immune tolerance induction in hemophilia A: systematic review and meta-analysis;Research and Practice in Thrombosis and Haemostasis;2023-01

4. Is there any place for replacement therapy of hemophilia A in children in present and future?;Russian Journal of Pediatric Hematology and Oncology;2022-11-09

5. Immune tolerance induction with a high-purity von Willebrand factor containing plasma-derived factor VIII concentrate in a child with hemophilia A with inhibitors;Pediatric Hematology/Oncology and Immunopathology;2022-06-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3